Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Income from Continuing Operations (2019 - 2025)

Cyclerion Therapeutics has reported Income from Continuing Operations over the past 7 years, most recently at 1006000.0 for Q3 2025.

  • Quarterly results put Income from Continuing Operations at 1006000.0 for Q3 2025, up 10.82% from a year ago — trailing twelve months through Sep 2025 was 3633000.0 (up 38.68% YoY), and the annual figure for FY2024 was 3628000.0, up 71.99%.
  • Income from Continuing Operations for Q3 2025 was 1006000.0 at Cyclerion Therapeutics, up from 1672000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CYCN hit a ceiling of 502000.0 in Q4 2024 and a floor of 16176000.0 in Q2 2021.
  • Median Income from Continuing Operations over the past 5 years was 3275000.0 (2023), compared with a mean of 5857736.84.
  • Biggest five-year swings in Income from Continuing Operations: crashed 33.13% in 2023 and later surged 127.97% in 2024.
  • Cyclerion Therapeutics' Income from Continuing Operations stood at 14338000.0 in 2021, then surged by 68.93% to 4455000.0 in 2022, then surged by 59.71% to 1795000.0 in 2023, then surged by 127.97% to 502000.0 in 2024, then tumbled by 300.4% to 1006000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 1006000.0 (Q3 2025), 1672000.0 (Q2 2025), and 1457000.0 (Q1 2025) per Business Quant data.